About DmX-like protein 1
DmX-like protein 1 (DMXL1) is a protein
from Homo sapiens identified by UniProt accession
Q9Y485, 3027 residues long.
MolForge cross-references it against 0 known binders and
30 disease associations.
Target properties
| Protein name | DmX-like protein 1 |
|---|
| UniProt accession | Q9Y485 |
|---|
| Gene | DMXL1 |
|---|
| Organism | Homo sapiens |
|---|
| Length | 3027 residues |
|---|
| Molecular weight | — |
|---|
| EC numbers | — |
|---|
| Target class | UNCLASSIFIED |
|---|
| Subcellular location | — |
|---|
| Keywords | — |
|---|
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
|---|
| Druggability score | — |
|---|
| Pocket score | — |
|---|
| Max clinical phase | — |
|---|
Disease associations (30)
Diseases linked to this target (Open Targets).
- neurodegenerative disease · score 0.39
- mean corpuscular volume · score 0.22
- diastolic blood pressure · score 0.20
- mean corpuscular hemoglobin · score 0.18
- mean corpuscular hemoglobin concentration · score 0.17
- leukocyte count · score 0.14
- adolescent idiopathic scoliosis · score 0.08
- red blood cell density measurement · score 0.08
- neuroimaging measurement · score 0.07
- brain measurement · score 0.05
3D Structure (10)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
Amino-acid sequence (3027 residues)
MNLHQVLTGA VNPGDHCFSV GSIGDQRFTA YASGCDIVIL GSDFERLQII PGAKHGNIQV GCVDCSMQQG KIAASYGNVI SIFEPVNLPK QKKNLELYSQ WQKSGQFFLE SIAHNITWDP TGSRLLTGSS YLQLWSNTNL EKPTEDENLN KTDLNFGDWK CIWHCKTASQ VHLMKFSPDG EFFATAGKDD CLLKVWYNVE NWRTAVTSPD GSSEKQSQGE IDFSFVYLAH PRAVNGFSWR KTSKYMPRAS VCNVLLTCCK DNVCRLWVET FLPNDCLLYG GDCSHWTESI NLTNNFKRNA SSKERVQNAL EVNLRHFRRG RRRSLALVAH TGYLPHQQDP HHVHRNTPLH ANALCHFHIA ASINPATDIP LLPSITSLSL NENEEKTGPF VVHWLNNKEL HFTLSMEVFL QQLRKSFEQP SSEASVEDSN QADVKSDEET DDGVDDLKIN PEKKELGCDK MVPNSSFTSL SSAAIDHQIE VLLSEWSKNA DMLFSIHPMD GSLLVWHVDW LDEYQPGMFR QVQVSFVSRI PVAFPTGDAN SLCKSIMMYA CTKNVDLAIQ QGKQKPSGLT RSTSMLISSG HNKSSNSLKL SIFTPNVMMI SKHADGSLNQ WLVSFAEESA FSTVLSISHK SRYCGHRFHL NDLACHSVLP LLLTTSHHNA LRTPDVDNPE QPFDALNIEE CSLTQQNKST VDVAFQDPSA VYSELILWRV DPVGPLSFSG GVSELARINS LHVSAFSNVA WLPTLIPSYC LGAYCNSPSA CFVASDGQYL RLYEAVIDAK KLLSELSNPE ISKYVGEVFN IVSQQSTARP GCIIALDPIT KLHGRKTQLL HVFEEDFILN NLEKKSLGKD SILSNAGSSP NGFSEKFYLI VIECTQDNRS LLHMWNLHLK SIPVSLDEKV DTKLSEAVWQ PEEHYSSSPE KILSPFSQKY QACRANLQST SRLTLFSEMV YSQELHLPEG VEIISIKPSA GHLSSSSIYP ACSAPYLLAT SCSDEKVRFW RCRVTDGESA TSKNGKIDLA YIWEEWPLLI EDGLQSNSSI TVPGRPVEVS CAHTNRLAVA YKQPASNSRS SQDFVMHVSI FECESTGGSC WVLEQTIHLD ELSTVLDSGI SVDSNLVAYN KQDMYLSSKE NITSNTKHLV HLDWMSREDG SHILTVGIGS KLFMYGPLAG KVQDQTGKET LAFPLWESTK VVPLSKFVLL RSVDLVSSVD GSPPFPVSLS WVRDGILVVG MDCEMHVYCQ WQPSSKQEPV ITDSYSGSTP SITSLIKQSN SSSGLHPPKK TLTRSMTSLA QKICGKKTAF DPSVDMEDSG LFEAAHVLSP TLPQYHPLQL LELMDLGKVR RAKAILSHLV KCIAGEVVAL NEAESNHERR LRSLTISASG STTRDPQAFN KAENTDYTEI DSVPPLPLYA LLAADDDSCY SSLEKSSNES TLSKSNQLSK ESYDELFQTQ LLMTDTHMLE TDEENTKPRV IDLSQYSPTY FGPEHAQVLS GHLLHSSLPG LSRMEQMSLM ALADTIATTS TDIGESRDRS QGGETLDECG LKFLLAVRLH TFLTTSLPAY RAQLLHQGLS TSHFAWAFHS VAEEELLNML PAMQKDDPTW SELRAMGVGW WVRNTRILRK CIEKVAKAAF YRKNDPLDAA IFYLAMKKKA VIWGLYRAEK NTRMTQFFGH NFEDERWRKA ALKNAFSLLG KQRFEHSAAF FLLAGCLRDA IEVCLEKLND IQLALVIARL YESEFDTSAA YKSILRKKVL GIDSPVSELC SLNINMHHDP FLRSMAYWIL EDYSGALETL IKQPIRENDD QVLSASNPTV FNFYNYLRTH PLLLRRHFGS SDTFSTHMSL TGKSGLAGTI NLSERRLFFT TASAHLKAGC PMLALEVLSK MPKVIKKTRP FYRASSFLDT SKDCSPSSPL KLDAREDKSS AVDWSQSLIN GFGSSSEGSS EKQSNSTLSF DWSQPSVVFQ DDSLELKWDS DNDEENEDVP ISMKELKPLQ RKTDKKLDDI SSNYTESFST LDENDLLNPS EDIIAVQLKF RACLKILTVE LRTLSTGYEI DGGKLRYQLY HWLEKEVIAL QRTCDFCSDA EELQSAFGRN EDEFGLNEDA EDLPHQTKVK QLRENFQEKR QWLLKYQSLL RMFLSYCILH GSHGGGLASV RMELILLLQE SQQETSEPLF SSPLSEQTSV PLLFACTANA KTVVANPLLH LSNLTHDILH AIINFDSPPH PDIQSNKVYV MHTLAASLSA CIYQCLCGSH NYSSFQTNQF TGMVYQTVLL PHRPSLKTGS LDEALTPNTS PAQWPGITCL IRLLNSSGEE AQSGLTVLLC EILTAVYLSL FIHGLATHSS NELFRIVAHP LNEKMWSAVF GGGAHVPSKE QTHSKTLPVS SLVEEGEKQN KRFRPSKMSC RESAPLTPSS APVSQESLAV KEKFIPPELS IWDYFIAKPF LPSSQSRAEY DSEESLGSDD DDNDDDDDVL ASDFHLQEHS NSNSYSWSLM RLAMVQLVLN NLKTFYPFAG HDLAELPVSS PLCHAVLKTL QCWEQVLLRR LEIHGGPPQN YIASHTAEES LSAGPAILRH KALLEPTNTP FKSKHHLALS VKRLWQYLVK QEEIQETFIK NIFTKKRCLN EIEADLGYPG GKARIIHKES DIITAFAVNK ANRNCIAIAS SHDVQELDVS GILATQVYTW VDDDIEVETK GSEDFLVIHA RDDLTAVQGT TPYTHSNPGT PINMPWLGST QTGRGASVMI KKAINNVRRM TSHPTLPYYL TGAQDGSVRM FEWGHSQQIT CFRSGGNSRV TRMRFNYQGN KFGIVDADGY LSLYQTNWKC CPVTGSMPKP YLTWQCHNKT ANDFVFVSSS SLIATAGLST DNRNVCLWDT LVAPANSLVH AFTCHDSGAT VLAYAPKHQL LISGGRKGFT YVFDLCQRQQ RQLFQSHDSP VKAVAVDPTE EYFVTGSAEG NIKIWSLSTF GLLHTFVSEH ARQSIFRNIG TGVMQIETGP ANHIFSCGAD GTMKMRILPD QFSPLNEVLK NDVKFML
Explore DmX-like protein 1 with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets